Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

OBX02-011

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Oncobix

Drug class:

EGFR inhibitor, ALK inhibitor

Related drugs:

ALK inhibitor (0)

cetuximab (347)

osimertinib (301)

erlotinib (235)

gefitinib (194)

panitumumab (123)

lapatinib (107)

neratinib (102)

brigatinib (50)

aumolertinib (39)

amivantamab-vmjw (25)

firmonertinib (14)

mobocertinib (12)

lazertinib (12)

tarloxotinib bromide (7)

nimotuzumab (6)

rociletinib (5)

tomuzotuximab (4)

necitumumab (3)

befotertinib (3)

zorifertinib (3)

ABP 494 (cetuximab biosimilar) (1)

BAY 2927088 (1)

Compound 6a (1)

abivertinib (1)

STI-001 (cetuximab biosimilar) (0)

antroquinonol (0)

zalutumumab (0)

JNJ-26483327 (0)

asandeutertinib (0)

PF-08046052 (0)

rindopepimut (0)

Undisclosed EGFR inhibitor (0)

cetuximab biosimilar (0)

PF-06747775 (0)

JNJ-64041757 (0)

crizotinib (312)

entrectinib (178)

alectinib (104)

lorlatinib (94)

ensartinib (42)

repotrectinib (27)

iruplinalkib (11)

unecritinib (6)

ALK inhibitor (0)

›

EGFR C797S + EGFR T790M + EGFR L858R	Non Small Cell Lung Cancer	EGFR C797S + EGFR T790M + EGFR L858R	Non Small Cell Lung Cancer	OBX02-011 Sensitive: D – Preclinical OBX02-011 Sensitive : D	OBX02-011 Sensitive: D – Preclinical OBX02-011 Sensitive : D
EGFR C797S	Non Small Cell Lung Cancer	EGFR C797S	Non Small Cell Lung Cancer	OBX02-011 Sensitive: D – Preclinical OBX02-011 Sensitive : D	OBX02-011 Sensitive: D – Preclinical OBX02-011 Sensitive : D